<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2123">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04711954</url>
  </required_header>
  <id_info>
    <org_study_id>1990 Study</org_study_id>
    <nct_id>NCT04711954</nct_id>
  </id_info>
  <brief_title>HIV/COV in Ukraine-NL</brief_title>
  <official_title>COVID-19 in People Living With HIV in Light of the 90-90-90 Goals: A Netherlands/Ukraine Research Collaboration.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lviv Regional AIDS Health Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Contradicting preliminary results are available on the impact of COVID-19 in people with HIV&#xD;
      (PWH). How achieving goals of the HIV 90-90-90 cascade of care influences the risk of&#xD;
      COVID-19 in PWH is unclear. The primary objective is to determine the impact of COVID-19 in&#xD;
      PWH cohorts from Ukraine and the Netherlands.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Prevalence COVID19</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Prevalence (percent) of clinical COVID-19 in PWH cohorts from Ukraine and in the Netherlands.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence COVID-19</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Incidence (nr cases/person years) of clinical COVID-19 cases in PWH cohorts from Ukraine and in the Netherlands</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WHO categories COVID-19</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Prevalence of no suspicion, possible, probable and proven COVID-19 cases in the past 6 months PWH cohorts from Ukraine and the Netherlands.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WHO categories COVID-19</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Incidence of no suspicion, possible, probable and proven COVID-19 cases in the past 6 months PWH cohorts from Ukraine and the Netherlands.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WHO disease severity COVID-19</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Proportion of COVID-19 patients according to the severity of COVID-19 on an adapted World Health Organisation 5 point disease severity scale (where 1=no symptoms, 2=symptoms but outpatient, 3=admitted to hospital, 4=admitted to ICU, 5=fatal) in people with HIV cohorts from Ukraine and the Netherlands.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroprevalence</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Anti-SARSCOV2 seroprevalence in PWH cohorts from Ukraine and the Netherlands</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NPV/PPV WHO categories COVID19</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Positive and negative predictive value of the WHO COVID-19 case probability categories on anti-SARSCOV2 serology in PWH cohort from Ukraine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Description of COVID-19 therapeutic management in PWH cohorts from Ukraine and the Netherlands</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictors for COVID-19</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Predictor variables for having clinical COVID-19 in PWH cohorts from Ukraine and the Netherlands according to 1) sex, 2) age categories (&lt;50, 50-70, &gt;70), 3) ART (LPV/r vs other and TDF containing vs non-TDF containing regimens), 4) most recent CD4+T-cell 5) HIV-RNA suppressed (&lt;=50 / &gt;50), 6) prior TB, 7) prior BCG, 8) HIV transmission group, 9) comorbidities (0 vs 1 vs &gt;1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictors for COVID-19 severity</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Predictor variables for the highest score on an ordinal scale for COVID-19 severity according to the adapted 5point WHO severity scale (where 1=no symptoms, 2=symptoms but outpatient, 3=admitted to hospital, 4=admitted to ICU, 5=fatal) in PWH cohorts from Ukraine and the Netherlands according to 1) sex, 2) age categories (&lt;50, 50-70, &gt;70), 3) ART (LPV/r vs other and TDF containing vs non-TDF containing regimens), 4) most recent CD4+T-cell 5) HIV-RNA suppressed (&lt;=50 / &gt;50), 6) prior TB, 7) prior BCG, 8) HIV transmission group, 9) comorbidities (0 vs 1 vs &gt;1)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>HIV vs non-HIV</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Correlation of HIV status with the highest score on an ordinal scale for COVID-19 severity according to the adapted 5point WHO severity scale (where 1=no symptoms, 2=symptoms but outpatient, 3=admitted to hospital, 4=admitted to ICU, 5=fatal) in matched PWH cases with HIV uninfected controls by age, sex and comorbidities.</description>
  </other_outcome>
  <other_outcome>
    <measure>PPV/NPV WHO categories COVID-19</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Positive and negative predictive value of the WHO COVID-19 case probability categories in the prior 3 months on anti-SARSCOV2 serology in PWH cohort from Ukraine</description>
  </other_outcome>
  <other_outcome>
    <measure>Effect of socio-economic status by questionnaire on COVID-19 incidence</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Evaluate the impact of social economic status on COVID-19 incidence.</description>
  </other_outcome>
  <other_outcome>
    <measure>Effect of socio-economic status on COVID-19 severity</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Evaluate the impact of social economic status on COVID-19 severity according to WHO 5 point scale (where 1=no symptoms, 2=symptoms but outpatient, 3=admitted to hospital, 4=admitted to ICU, 5=fatal)</description>
  </other_outcome>
  <other_outcome>
    <measure>Symptoms</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Describe symptoms associated with COVID probability in PWH cohorts from Ukraine and the Netherlands</description>
  </other_outcome>
  <other_outcome>
    <measure>Rapid Ag test</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Evaluate the PPV/NPV of the rapid antigen test in PWH with symptoms suspected of COVID-19 in Ukraine and the Netherlands</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Hiv</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>ATHENA</arm_group_label>
    <description>Cohort of people living with HIV in the Netherlands</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LUKCY</arm_group_label>
    <description>Cohort of people living with HIV in the Lviv area, Ukraine</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        People with HIV from patient cohorts in the Netherlands and Ukraine. All participants will&#xD;
        be systematically included consecutively.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        HIV infected No registered objection to use of data&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Casper Rokx, MD PhD</last_name>
    <phone>0681336328</phone>
    <email>c.rokx@erasmusmc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Casper Rokx, MD PhD</last_name>
      <phone>0681336328</phone>
      <email>c.rokx@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>Albert Groenendijk, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lviv Regional AIDS Health Center</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Vasylyev, MD</last_name>
      <email>marta.vasylyev@astar.com.ua</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 12, 2021</study_first_submitted>
  <study_first_submitted_qc>January 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2021</study_first_posted>
  <last_update_submitted>January 13, 2021</last_update_submitted>
  <last_update_submitted_qc>January 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Casper Rokx</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Other research group can contact the PI with a research question to gain access to IPD.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data will be kept up to 15 years</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

